New oral drug hopes to tackle Hard-to-Treat blood cancers
NCT ID NCT05024045
First seen Mar 04, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. The study lasts up to 3 years and also tests LOXO-338 combined with another drug, pirtobrutinib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU de Montpellier-Hopital St Eloi
Montpellier, 34295, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, Cedex, 69495, France
-
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
Nantes, 44093, France
-
Centre hospitalier universitaire de Haut Leveque
Pessac, 33604, France
-
Centrum Medyczne Pratia Poznan
Skorzewo, Poznan, 60 185, Poland
-
City of Hope National Medical Center
Duarte, California, 91010-0269, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
IRCCS - AOU di Bologna
Bologna, 40138, Italy
-
Indiana Blood & Marrow Transplantation (IBMT)
Indianapolis, Indiana, 46237, United States
-
Institut Curie
Paris, 75248, France
-
L'Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, Cedex 9, 31100, France
-
Mayo Clinic
Rochester, Minnesota, 55905-0002, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, 02-781, Poland
-
Pratia MCM Krakow
Krakow, 30-510, Poland
-
Swedish Medical Center
Seattle, Washington, 98104, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of California San Francisco, Medical Center at Paranassus
San Francisco, California, 94117, United States
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LOXO-338 (a BCL-2 inhibitor, taken as a pill)
What this could lead to
If it works, this could lead to a new treatment option for people with advanced blood cancers that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) study, so the drug may not work or could have serious side effects. It is only for people who have already tried standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.